Intellia Therapeutics (NTLA) Revenue (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Revenue data on file, last reported at $15.0 million in Q1 2026.

• On a quarterly basis, Revenue fell 9.5% year-over-year to $15.0 million in Q1 2026; TTM through Mar 2026 was $66.1 million, a 45.04% increase from a year earlier, with the FY2025 full-year figure at $67.7 million, up 16.92% from the prior year.
• Revenue for Q1 2026 stood at $15.0 million, down from $23.0 million in the prior quarter.
• Over the last five years, Revenue for NTLA reached as high as $28.9 million in Q1 2024 and fell as low as -$1.9 million in Q4 2023.
• Historically, Revenue has averaged $13.5 million across 5 years, with a median of $13.6 million in 2022.
• Across the five-year window, Revenue slumped 114.12% in 2023 and surged 771.57% in 2024, its largest moves.
• Year by year, Revenue stood at $13.6 million in 2022, then slumped by 114.12% to -$1.9 million in 2023, then surged by 771.57% to $12.9 million in 2024, then jumped by 78.79% to $23.0 million in 2025, then tumbled by 34.62% to $15.0 million in 2026.
• Per Business Quant data, the three most recent Revenue figures were $15.0 million in Q1 2026, $23.0 million in Q4 2025, and $13.8 million in Q3 2025.